2017-04-19 05:07:24 UTC

Does Good Oral Health Increase Risk for IBD?

A population-based cohort study of more than 20,000 people in Sweden associated poor oral health with reduced risk for inflammatory bowel diseases (IBD). The article, in the April issue of Clinical Gastroenterology and Hepatology, reports that the protective effect increases with the severity of poor dental hygiene.

Environmental factors, such as westernization and modernization, are thought to contribute to the increasing worldwide prevalence of IBD. Improved hygiene has reduced human exposures to microbes, which is believed to increase risk for autoimmune disorders such as IBD.

Weiyao Yin et al performed a prospective cohort study of the association between poor oral health and risk of IBD in 20,162 persons in Sweden. Participants in the population-based survey (15 years or older) were offered clinical oral examinations and asked to respond to questionnaires, and followed from January 1973 through December 2012. Subjects with IBD were identified from the National Patient Register.

IBD was diagnosed in 209 individuals, for an incidence rate of 37.3 per 100,000 person-years. Among them, 142 had UC (68%) and 67 had CD (32%), with incidence rates of 25.3 and 12.0 per 100,000 person-years, respectively.

People with severe lack of oral hygiene (5–6 teeth missing) had a 44% lower risk of IBD than people who had not lost any teeth, and a 45% lower risk of ulcerative colitis. This protective effect strengthened with deterioration of oral hygiene for IBD and ulcerative colitis. Hazard ratios were similar in men and women.

Unacceptable levels of dental plaques (accumulation of biofilms, containing various bacterial species, on tooth surfaces and in subgingival areas) were associated with a 68% lower risk of Crohn’s disease—risk decreased further with severe plaque accumulation. However, the authors found no association between dental plaque and UC.

Oral mucosal lesions seemed to reduce risk for IBD, ulcerative colitis, and Crohn’s disease. The effect of fungal-associated oral mucosal leasions was greatest, reducing risk for IBD by 29%, ulcerative colitis by 23%, and Crohn’s disease by 39%. However, none of the observed associations reached statistical significance.

Previous studies have correlated changes in oral bacteria with intestinal microbiomes of patients with IBD. Less abundant microflora in the gut mucosa associated with reduced diversity (overall and in specific phyla, such as Fusobacteria and Firmicutes) in tongue and buccal mucosa of patients with Crohn’s disease.

Yin et al propose that excessive oral hygiene might lead to dysbiosis, which deregulates innate immune responses and promotes inflammation. Conversely, poor oral health might contribute to induction of immune tolerance and suppression of over-reactive inflammationthis might reduce the risk of immune-mediated diseases such as IBD.

Yin at al add that plaque-induced oral mucosal inflammation, such as gingivitis and periodontits, as well as oral cancer, have been linked to IBD. However, the high prevalence of oral health problems among patients with IBD does not contradict a model in which excessive oral hygiene and dysbiosis contribute to IBD and its oral complications.

The authors state that they do not discourage oral hygiene, but that overprotective daily hygiene might be considered as a factor involved in development of IBD.

 

More on Crohn's Disease

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Jan. 18, 2018

Expand your knowledge, network with IBD leaders, spark innovative research and get inspired to improve patient care.

Putting Patients First: Digital Health Tools to Empower IBD Patients

Jan. 18, 2018

Discover how advances in digital health can help you monitor and support IBD patients remotely and dynamically, improve face-to-face care, and drive clinical decisions through shared decision-making.

Get Your Questions Answered on Biosimilar Therapies

Dec. 7, 2017

Join inflammatory bowel disease (IBD) experts on Dec. 11, 2017, 8-8:45 p.m. ET, for a free webinar on biosimilar therapies.